Internal medicine

Pathology

Clinical endpoint

Placebo

Progression-free survival

Cancer

Oncology

Exemestane

Metastatic breast cancer

Alternative medicine

Neutropenia

Aromatase

Aromatase inhibitor

Chemotherapy

Palbociclib

Fulvestrant

Breast cancer

Clinical trial

Medicine

Estrogen receptor

The Lancet Oncology

Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial